Welcome to LookChem.com Sign In|Join Free
  • or
2,4-dihydro-3-methyl-2-phenethyl-3H-pyrazol-3-one, commonly known as Praziquantel, is a chemical compound that serves as an anthelmintic medication. It is specifically designed to treat parasitic worm infections, demonstrating effectiveness against a broad spectrum of parasites such as tapeworms, flukes, and schistosomes. Praziquantel operates by compromising the structural integrity of the parasites' cell membranes, leading to their paralysis and subsequent death. This medication is widely utilized in both human and veterinary medicine, recognized for its safety and efficacy when administered as directed. However, it is important to note that, like all medications, Praziquantel may have side effects and should be used under the supervision of a healthcare professional.

131-65-7

Post Buying Request

131-65-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

131-65-7 Usage

Uses

Used in Pharmaceutical Industry:
2,4-dihydro-3-methyl-2-phenethyl-3H-pyrazol-3-one is used as an anthelmintic agent for the treatment of various parasitic worm infections. It is effective in combating a range of parasites, including tapeworms, flukes, and schistosomes, due to its ability to disrupt the cell membranes of these parasites, resulting in their paralysis and death.
Used in Veterinary Medicine:
In the veterinary field, 2,4-dihydro-3-methyl-2-phenethyl-3H-pyrazol-3-one is utilized as a medication to treat and control parasitic worm infections in animals. Its broad-spectrum efficacy makes it a valuable tool in maintaining the health of various animal species.
Used in Human Medicine:
2,4-dihydro-3-methyl-2-phenethyl-3H-pyrazol-3-one is also used in human medicine as an anthelmintic to treat infections caused by parasitic worms. Its safety and effectiveness make it a preferred choice for healthcare professionals when addressing such infections.

Check Digit Verification of cas no

The CAS Registry Mumber 131-65-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,3 and 1 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 131-65:
(5*1)+(4*3)+(3*1)+(2*6)+(1*5)=37
37 % 10 = 7
So 131-65-7 is a valid CAS Registry Number.
InChI:InChI=1/C12H14N2O/c1-3-10-6-4-5-7-11(10)14-12(15)8-9(2)13-14/h4-7H,3,8H2,1-2H3

131-65-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(2-ethylphenyl)-5-methyl-4H-pyrazol-3-one

1.2 Other means of identification

Product number -
Other names 1-(2-Ethylphenyl)-3-methyl-2-pyrazolin-5-on

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:131-65-7 SDS

131-65-7Relevant academic research and scientific papers

Diversification of edaravone via palladium-catalyzed hydrazine cross-coupling: Applications against protein misfolding and oligomerization of beta-amyloid

Maclean, Mark A.,Diez-Cecilia, Elena,Lavery, Christopher B.,Reed, Mark A.,Wang, Yanfei,Weaver, Donald F.,Stradiotto, Mark

, p. 100 - 104 (2015/12/18)

N-Aryl derivatives of edaravone were identified as potentially effective small molecule inhibitors of tau and beta-amyloid aggregation in the context of developing disease-modifying therapeutics for Alzheimer's disease (AD). Palladium-catalyzed hydrazine monoarylation protocols were then employed as an expedient means of preparing a focused library of 21 edaravone derivatives featuring varied N-aryl substitution, thereby enabling structure-activity relationship (SAR) studies. On the basis of data obtained from two functional biochemical assays examining the effect of edaravone derivatives on both fibril and oligomer formation, it was determined that derivatives featuring an N-biaryl motif were four-fold more potent than edaravone.

P2Y1 receptor antagonists as novel antithrombotic agents

Pfefferkorn, Jeffrey A.,Choi, Chulho,Winters, Thomas,Kennedy, Robert,Chi, Liguo,Perrin, Lisa A.,Lu, Gina,Ping, Yun-Wen,McClanahan, Tom,Schroeder, Richard,Leininger, Michael T.,Geyer, Andrew,Schefzick, Sabine,Atherton, James

body text, p. 3338 - 3343 (2009/04/06)

The P2Y1 and P2Y12 purinergic receptors are responsible for mediating adenosine diphosphate (ADP) dependent platelet aggregation. Evidence from P2Y1 knockout studies as well as from nucleotide-based small molecule P2Y1 antagonists has suggested that the antagonism of this receptor may offer a novel and effective method for the treatment of thrombotic disorders. Herein, we report the identification and optimization of a series of non-nucleotide P2Y1 antagonists that are potent and orally bioavailable.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 131-65-7